Salud financiera de hoja de balance de Arvinas

Salud financiera controles de criterios 5/6

Arvinas tiene unos fondos propios totales de $457.2M y una deuda total de $1,000.0K, lo que sitúa su ratio deuda/fondos propios en 0.2%. Sus activos y pasivos totales son $1.1B y $601.1M respectivamente.

Información clave

0.1%

Ratio deuda-patrimonio

US$800.00k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$1.26b
Patrimonio	US$660.00m
Total pasivo	US$644.60m
Activos totales	US$1.30b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Feb 07

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer

Nov 19

Análisis de la situación financiera

Pasivos a corto plazo: ARVNLos activos a corto plazo ($1.0B) de la empresa superan a sus pasivos a corto plazo ($317.3M).

Pasivo a largo plazo: ARVNLos activos a corto plazo ($1.0B) superan a sus pasivos a largo plazo ($283.8M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ARVN tiene más efectivo que su deuda total.

Reducción de la deuda: ARVN ha pasado de 6% a 0.2% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ARVN tiene suficiente cash runway para más de 3 años basándose en su free cash flow actual.

Pronóstico de cash runway: Datos insuficientes para determinar si ARVN tiene suficiente margen de liquidez en caso de que su flujo de caja libre siga creciendo o disminuyendo en función de las tasas históricas.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Arvinas

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

Consensus EPS estimates fall by 12%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

CFO & Treasurer exercised options and sold US$810k worth of stock

Chief Scientific Officer exercised options to buy US$226k worth of stock.

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Chief Scientific Officer notifies of intention to sell stock

Arvinas, Inc. Announces Completed Phase 1 and Interim Phase 2 ARDENT Data for Bavdegalutamide (ARV-110), A Novel PROTAC® Degrader Targeting the Androgen Receptor

Arvinas, Inc. Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 Ardent Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to Present At 2022 ASCO GU Meeting

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Independent Director exercised options and sold US$793k worth of stock

Chief Medical Officer exercised options and sold US$782k worth of stock

CFO & Treasurer notifies of intention to sell stock

Independent Director recently sold US$24m worth of stock

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

Consensus forecasts updated

Consensus forecasts updated

No longer forecast to breakeven

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer

Chief Scientific Officer exercised options and sold US$1.3m worth of stock

Independent Director recently sold US$12m worth of stock

Independent Director exercised options and sold US$1.1m worth of stock